BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lamb YN. Pitolisant: A Review in Narcolepsy with or without Cataplexy. CNS Drugs 2020;34:207-18. [PMID: 31997137 DOI: 10.1007/s40263-020-00703-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 13.0] [Reference Citation Analysis]
Number Citing Articles
1 Pascual-Gilabert M, López-Castel A, Artero R. Myotonic dystrophy type 1 drug development: A pipeline toward the market. Drug Discov Today 2021;26:1765-72. [PMID: 33798646 DOI: 10.1016/j.drudis.2021.03.024] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Yoshikawa T, Nakamura T, Yanai K. Histaminergic neurons in the tuberomammillary nucleus as a control centre for wakefulness. Br J Pharmacol 2021;178:750-69. [PMID: 32744724 DOI: 10.1111/bph.15220] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
3 St Louis EK, Videnovic A. Sleep Neurology's Toolkit at the Crossroads: Challenges and Opportunities in Neurotherapeutics Lost and Found in Translation. Neurotherapeutics 2021;18:1-5. [PMID: 33821447 DOI: 10.1007/s13311-021-01032-7] [Reference Citation Analysis]
4 Hino N, Marumo T, Kotani M, Shimazaki T, Kaku-fukumoto A, Hikichi H, Karasawa J, Tomishima Y, Komiyama H, Tatsuda E, Nozawa D, Nakamura T, Chaki S. A Novel Potent and Selective Histamine H 3 Receptor Antagonist Enerisant: In Vitro Profiles, In Vivo Receptor Occupancy, and Wake-Promoting and Procognitive Effects in Rodents. J Pharmacol Exp Ther 2020;375:276-85. [DOI: 10.1124/jpet.120.000185] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
5 Łażewska D, Olejarz-Maciej A, Reiner D, Kaleta M, Latacz G, Zygmunt M, Doroz-Płonka A, Karcz T, Frank A, Stark H, Kieć-Kononowicz K. Dual Target Ligands with 4-tert-Butylphenoxy Scaffold as Histamine H3 Receptor Antagonists and Monoamine Oxidase B Inhibitors. Int J Mol Sci 2020;21:E3411. [PMID: 32408504 DOI: 10.3390/ijms21103411] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Łażewska D, Bajda M, Kaleta M, Zaręba P, Doroz-Płonka A, Siwek A, Alachkar A, Mogilski S, Saad A, Kuder K, Olejarz-Maciej A, Godyń J, Stary D, Sudoł S, Więcek M, Latacz G, Walczak M, Handzlik J, Sadek B, Malawska B, Kieć-Kononowicz K. Rational design of new multitarget histamine H3 receptor ligands as potential candidates for treatment of Alzheimer's disease. Eur J Med Chem 2020;207:112743. [PMID: 32882609 DOI: 10.1016/j.ejmech.2020.112743] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
7 Terasaka S, Hachiuma K, Mano Y, Onishi K, Kitajima I, Nishino I, Endo H. Drug-drug interaction potential and clinical pharmacokinetics of enerisant, a novel potent and selective histamine H3 receptor antagonist. Xenobiotica 2021;51:786-95. [PMID: 33910470 DOI: 10.1080/00498254.2021.1918361] [Reference Citation Analysis]
8 Zhang M, Tang L, Jiang L, Wei J, Hu Y, Sheng R. Identification of N-phenyl-3-methoxy-4-pyridinones as orally bioavailable H3 receptor antagonists and β-amyloid aggregation inhibitors for the treatment of Alzheimer's disease. Eur J Med Chem 2021;212:113096. [PMID: 33395621 DOI: 10.1016/j.ejmech.2020.113096] [Reference Citation Analysis]
9 Guevarra JT, Hiensch R, Varga AW, Rapoport DM. Pitolisant to Treat Excessive Daytime Sleepiness and Cataplexy in Adults with Narcolepsy: Rationale and Clinical Utility. Nat Sci Sleep 2020;12:709-19. [PMID: 33117007 DOI: 10.2147/NSS.S264140] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
10 Cataldi M, Arnaldi D, Tucci V, De Carli F, Patti G, Napoli F, Pace M, Maghnie M, Nobili L. Sleep disorders in Prader-Willi syndrome, evidence from animal models and humans. Sleep Med Rev 2021;57:101432. [PMID: 33567377 DOI: 10.1016/j.smrv.2021.101432] [Reference Citation Analysis]
11 Dondé C, Polosan M, Guzun R. Pitolisant for Treating Narcolepsy Comorbid With Schizophrenia. J Clin Psychopharmacol 2020;40:504-6. [DOI: 10.1097/jcp.0000000000001243] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Cheng L, Liu J, Chen Z. The Histaminergic System in Neuropsychiatric Disorders. Biomolecules 2021;11:1345. [PMID: 34572558 DOI: 10.3390/biom11091345] [Reference Citation Analysis]
13 Lehert P. Efficacy of Pitolisant 20 mg in Reducing Excessive Daytime Sleepiness and Fatigue in Patients with Obstructive Sleep Apnoea Syndrome: An Individual Patient Data Meta-analysis. Clin Drug Investig 2021. [PMID: 34859394 DOI: 10.1007/s40261-021-01104-8] [Reference Citation Analysis]
14 de Biase S, Pellitteri G, Gigli GL, Valente M. Evaluating pitolisant as a narcolepsy treatment option. Expert Opin Pharmacother 2021;22:155-62. [PMID: 32941089 DOI: 10.1080/14656566.2020.1817387] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
15 Meskill GJ, Davis CW, Zarycranski D, Doliba M, Schwartz JC, Dayno JM. Clinical Impact of Pitolisant on Excessive Daytime Sleepiness and Cataplexy in Adults With Narcolepsy: An Analysis of Randomized Placebo-Controlled Trials. CNS Drugs 2021. [PMID: 34935103 DOI: 10.1007/s40263-021-00886-x] [Reference Citation Analysis]
16 Espinosa-bustos C, Leitzbach L, Añazco T, Silva MJ, Campo AD, Castro-alvarez A, Stark H, Salas CO. Substituted Purines as High-Affinity Histamine H3 Receptor Ligands. Pharmaceuticals 2022;15:573. [DOI: 10.3390/ph15050573] [Reference Citation Analysis]